- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001240
Evaluating Patients With Abnormal Levels of Gastric Acid
Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion
This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid. The level of gastric acid is measured by analyzing the gastric juices of each individual patient. The gastric acid sample is obtained by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the nose to the stomach.
Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.
Study Overview
Status
Conditions
Detailed Description
Study Type
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Collaborators and Investigators
Publications and helpful links
General Publications
- McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):939-44. doi: 10.1016/s0016-5085(85)80011-1.
- Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):1026-33. doi: 10.1016/s0016-5085(85)80024-x.
- Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986 Oct 24;81(4B):49-59. doi: 10.1016/0002-9343(86)90600-5.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Pancreatic Diseases
- Paraneoplastic Syndromes
- Acid-Base Imbalance
- Pancreatic Neoplasms
- Carcinoma, Islet Cell
- Paraneoplastic Endocrine Syndromes
- Gastrinoma
- Zollinger-Ellison Syndrome
- Achlorhydria
Other Study ID Numbers
- 890005
- 89-DK-0005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrinoma
-
National Cancer Institute (NCI)CompletedLocally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine TumorUnited States, Canada
-
Laser Tissue Welding, Inc.National Cancer Institute (NCI); CHI St. Luke's Health, TexasCompletedPancreatic Neoplasms | Pancreatic Adenocarcinoma | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Polypeptide Tumor | Pancreatic Pseudocyst | Pancreatic Glucagonoma | Pancreas Injury | Pancreatic Cystadenoma | Pancreatic Tumor, Benign | Pancreas; Insulinoma | Pancreatic Teratoma | Pancreatic Vipoma and other conditionsUnited States
-
National Institute of Diabetes and Digestive and...CompletedGastrinoma | Zollinger Ellison SyndromeUnited States
-
British Columbia Cancer AgencyWithdrawnNeuroendocrine Tumors | Carcinoid Tumor | Gastrinoma | Insulinoma | Vipoma | Gastroenteropancreatic Neuroendocrine Tumor | Pulmonary Carcinoid TumorCanada
-
AstraZenecaCompletedZollinger-Ellison SyndromeUnited States, France
-
National Institute of Diabetes and Digestive and...CompletedZollinger Ellison SyndromeUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)WithdrawnGastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingGastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Islet Cell CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)TerminatedLiver Metastases | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | SomatostatinomaUnited States